Abstract

Research Article

Non-adherence to Drug Therapy for Hypertension is Critical and Underestimated in Mexican Patients: A Study from the First Contact Level

Martin Rosas-Peralta*, Rodrigo Villaseñor-Hidalgo, Héctor Galván-Oseguera, Luis Alcocer, Enrique Diaz-Diaz, Adolfo Chávez-Mendoza, Ernesto Cardona-Muñoz, Humberto Álvarez-López, José Manuel Enciso-Muñoz, Silvia Palomo-Piñón and Laurent Smail

Published: 10 July, 2025 | Volume 9 - Issue 1 | Pages: 009-014

Adherence, in a healthcare context, refers to the extent to which a person’s behavior aligns with recommendations from a healthcare provider. This can involve taking medication as prescribed, following a specific diet, or adhering to lifestyle changes. Although it is known that adherence is critical and requires a special approach to health, in Mexico, there are few studies on this issue. We confirm the information collected from 786 patients using an original questionnaire (AFEC) in Spanish, previously validated. Perfect adherence was detected in only 179 (22.8%), good adherence in 334 (42.5%), and nonadherence in 452 (57.5%). The age, obesity, and number of comorbidities were significantly associated with non-adherence (p < 0.05). Special strategies to approach this critical problem in health need to be reconsidered in Mexico. Non-adherence may help explain the low control rate of Mexican patients and the high rate of cardiovascular mortality.

Read Full Article HTML DOI: 10.29328/journal.ach.1001038 Cite this Article Read Full Article PDF

Keywords:

Hypertension; Adherence; Control rate; Mexico

References

  1. Campos-Nonato I, Oviedo-Solís C, Hernández-Barrera L, Márquez-Murillo M, Gómez-Álvarez E, Alcocer-Díaz L, et al. Detección, atención y control de hipertensión arterial. Salud Publica Mex. 2024;66(4):539-548. Spanish. Available from: https://doi.org/10.21149/15867
  2. Meaney E, Pérez-Robles E, Ortiz-Flores M, Perez-Ishiwara G, Meaney A, Munguía L, et al. Overweight, obesity, and age are the main determinants of cardiovascular risk aggregation in the current Mexican population: the FRIMEX III study. J Clin Med. 2024;13(8):2248. Available from: https://doi.org/10.3390/jcm13082248
  3. Díaz-Barreiro LA, Alcocer A, Álvarez-López H, Ancona-Vadillo AE, Antonio-Villa NE, Barquera S, et al. The MACARENHA connection: a holistic approach to understand and fight the cardiometabolic epidemics that ravage Mexico. Cardiovasc Metab Sci. 2025;36(1):5-7. Available from: https://www.medigraphic.com/pdfs/cardiovascuar/cms-2025/cms251a.pdf
  4. Burnier M. Drug adherence in hypertension. Pharmacol Res. 2017;125:142-149. Available from: https://doi.org/10.1016/j.phrs.2017.08.015
  5. Campos-Nonato I, Hernández-Barrera L, Flores-Coria A, Gómez-Álvarez E, Barquera S. Prevalencia, diagnóstico y Control of high blood pressure in vulnerable Mexican adults. Results of the Ensanut 100k. Salud Publica Mex. 2019;61:888-897. Available from: https://doi.org/10.21149/10574
  6. Rosas PM, Ramirez AE, Borrayo SG. An adherence self-report questionnaire in Spanish facilitated the adherence evaluation to cardiovascular drugs for secondary prevention after a ST-segment elevation myocardial infarction (STEMI). J Heart Cardiovasc Med. 2018;1(1):004-013. Available from: https://www.journalofhcvm.com/articles/JHCVM-v1-1001.pdf (Assumed URL as it was missing)
  7. Feinstein A. Multivariable analysis: an introduction. New Haven: Yale Univ Pr Verlag; 1996. Available from: https://www.jstor.org/stable/j.ctt2250wks
  8. Schutte AE, Srinivasapura Venkateshmurthy N, Mohan S, Prabhakaran D. Hypertension in low- and middle-income countries. Circ Res. 2021;128(7):808-826. Available from: https://doi.org/10.1161/circresaha.120.318729
  9. Gavrilova A, Bandere D, Rutkovska I, Šmits D, Mauriņa B, Poplavska E, et al. Knowledge about disease, medication therapy, and related medication adherence levels among patients with hypertension. Medicina (Kaunas). 2019 Oct 28;55(11):715. Available from: https://doi.org/10.3390/medicina55110715
  10. Souza AC, Borges JW, Moreira TM. Quality of life and treatment adherence in hypertensive patients: systematic review with meta-analysis. Rev Saude Publica. 2016;50:71. Available from: https://doi.org/10.1590/s1518-8787.2016050006415
  11. Robles NR, Macias JF. Hypertension in the elderly. Cardiovasc Hematol Agents Med Chem. 2015;12(3):136-145. Available from: https://doi.org/10.2174/1871525713666150310112350
  12. Le Bozec A, Korb-Savoldelli V, Boiteau C, Dechartres A, Al Kahf S, Sitbon O, et al. Medication adherence, related factors, and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review. Eur Respir Rev. 2024;33(173):240006. Available from: https://doi.org/10.1183/16000617.0006-2024
  13. Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1-15. Available from: https://doi.org/10.1016/j.ejim.2024.05.033
  14. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Oct 7;45(38):3912-4018. Available from: https://doi.org/10.1093/eurheartj/ehae178
  15. Camafort M, Kreutz R, Cho MC. Diagnosis and management of resistant hypertension. Heart. 2024;110(22):1336-1342. Available from: https://doi.org/10.1136/heartjnl-2022-321730
  16. Palomo-Piñón S, Antonio-Villa NE, García-Cortés LR, Moreno-Noguez M, Alcocer L, Álvarez-López H, et al. Patients living with arterial hypertension in Mexico: first insights of the Mexican Registry of Arterial Hypertension (RIHTA Study). Am J Hypertens. 2024;37(7):503-513. Available from: https://doi.org/10.1093/ajh/hpae024
  17. Alcocer L, Palomo S, Rangel-Zertuche RA, Berumen-Lechuga MG, Medina-Serrano JM, García-Cortés LR, et al. May Measurement Month 2021: an analysis of blood pressure screening results from Mexico. Eur Heart J Suppl. 2024;26(Suppl 3):iii58-iii60. Available from: https://doi.org/10.1093/eurheartjsupp/suae055
  18. Lane D, Lawson A, Burns A, Azizi M, Burnier M, Jones DJL, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension. 2022;79(1):12-23. Available from: https://doi.org/10.1161/hypertensionaha.121.17596
  19. Maniki PT, Chaar BB, Aslani P. Impact of interventions on medication adherence in patients with coexisting diabetes and hypertension. Health Expect. 2024;27(5):e70010. Available from: https://doi.org/10.1111/hex.70010
  20. Dean YE, Motawea KR, Shebl MA, Elawady SS, Nuhu K, Abuzuaiter B, et al. Adherence to antihypertensives in the United States: a comparative meta-analysis of 23 million patients. J Clin Hypertens (Greenwich). 2024;26(4):303-313. Available from: https://doi.org/10.1111/jch.14788
  21. Uchmanowicz B, Chudiak A, Uchmanowicz I, Rosińczuk J, Froelicher ES. Factors influencing adherence to treatment in older adults with hypertension. Clin Interv Aging. 2018;13:2425-2441. Available from: https://doi.org/10.2147/cia.s182881
  22. Saadat Z, Nikdoust F, Aerab-Sheibani H, Bahremand M, Shobeiri E, Saadat H, et al. Adherence to antihypertensives in patients with comorbid conditions. Nephrourol Mon. 2015;7(4):e29863. Available from: https://doi.org/10.5812/numonthly.29863
  23. Lee JS, Segura Escano R, Therrien NL, Kumar A, Bhatt A, Pollack LM, et al. Antihypertensive medication adherence and medical costs, health care use, and labor productivity among people with hypertension. J Am Heart Assoc. 2024;13(21):e037357. Available from: https://doi.org/10.1161/jaha.124.037357

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?